Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Apr 1.

Published in final edited form as: Biochem Pharmacol. 2021 Feb 10;186:114462. doi: 10.1016/j.bcp.2021.114462

Table 2.

Effects of flavonoids and CDK9 inhibitors on inhibiting LRA-induced provirus expression in J-Lat 9.2, J-Lat 10.6, and OM10.1 cells.

	J-Lat 9.2
Compound	TNFα EC₅₀ (μM)	Panobinostat EC₅₀ (μM)	Prostratin EC₅₀ (μM)
Chrysin	4.0 ± 0.4	2.8 ± 0.4	4.3 ± 1.2
Apigenin	5.6 ± 0.6	4.1 ± 0.4	7.3 ± 1.1
Luteolin	7.6 ± 0.6	6.8 ± 0.8	20.6 ± 2.6
L7G	4.5 ± 0.6	4.3 ± 0.4	17.3 ± 2.2
Naringenin	>30	>30	>30
Flavopiridol	0.008 ± 0.0004	0.028 ± 0.003	0.009 ± 0.001
Atuveciclib	1.7 ± 0.2	3.6 ± 0.8	1.8 ± 0.1

	J-Lat 10.6			OM-10.1
Compound	TNFα EC₅₀ (μM)	JQ1 EC₅₀ (μM)	HMBA EC₅₀ (μM)	TNFα EC₅₀ (μM)
Chrysin	6.3 ± 0.7	7.7 ± 1.5	6.7 ± 1.4	4.7 ± 0.3
Apigenin	6.2 ± 0.3	7.2 ± 1.1	5.2 ± 0.8	4.1 ± 0.8
Luteolin	13.6 ± 0.8	15.4 ± 1.5	26.5 ± 5.8	10.3 ± 0.6
L7G	11.9 ± 0.5	16.4 ± 3.3	10.1 ± 3.5	10.3 ± 1.2
Naringenin	>30	>30	>30	>30
Flavopiridol	0.019 ± 0.001	0.014 ± 0.002	0.099 ± 0.002	0.013 ± 0.0008
Atuveciclib	4.3 ± 0.2	2.4 ± 0.2	1.8 ± 0.1	1.8 ± 0.09